- Email: [email protected]
Genomic-Based Personalized Treatment for Gastric Cancer
Annals of Oncology 25 (Supplement 5): v17, 2014 doi:10.1093/annonc/mdu408.4
International Session 1: ‘Future perspective of therapeutic strategy for metastatic gastric cancer’ IS1
7
GENOMIC-BASED PERSONALIZED TREATMENT FOR GASTRIC CANCER
Sun Young Rha Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Korea
and recently several trials had been failed. The possible explanations are 1) heterogeneous and complex biology of gastric cancer, 2) relative lack of biologic information of gastric cancer, 3) difficulties in translational research from tissue heterogeneity, 4) not having enough and proper in vitro and in vivo model systems, and 5) lack of effective drug development strategy specific for gastric cancer. However, considering the accumulation of experiences from recent global trials and development of biotechnology for translational research, it is the time to leap-up to develop better treatment for improving outcome of GC. The various treatment efficacy and toxicities due to tumor heterogeneity are the major obstacles in cancer treatment. In addition, the genetic diversities of the host play a significant role in various efficacy and toxicity to systemic treatment. As the biology and genomics are improved, we could understand the molecular landscape of GC more deeply for identifying better targets. Also, the genome-wide evaluation of potential biomarkers for predicting treatment efficacy and toxicity becomes one of the significant approaches for the personalized medicine. Here, I will introduce the current status of genome-based drug development approaching personalized treatment in gastric cancer.
abstracts
After trastuzumab was introduced in treatment of Her-2 positive gastric cancer(GC), there are no specific and effective molecular targeted agents (MTA) in gastric cancer,
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v17/2240151 by guest on 14 March 2018
International Session 1: ‘Future perspective of therapeutic strategy for metastatic gastric cancer’ IS1
7
GENOMIC-BASED PERSONALIZED TREATMENT FOR GASTRIC CANCER
Sun Young Rha Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Korea
and recently several trials had been failed. The possible explanations are 1) heterogeneous and complex biology of gastric cancer, 2) relative lack of biologic information of gastric cancer, 3) difficulties in translational research from tissue heterogeneity, 4) not having enough and proper in vitro and in vivo model systems, and 5) lack of effective drug development strategy specific for gastric cancer. However, considering the accumulation of experiences from recent global trials and development of biotechnology for translational research, it is the time to leap-up to develop better treatment for improving outcome of GC. The various treatment efficacy and toxicities due to tumor heterogeneity are the major obstacles in cancer treatment. In addition, the genetic diversities of the host play a significant role in various efficacy and toxicity to systemic treatment. As the biology and genomics are improved, we could understand the molecular landscape of GC more deeply for identifying better targets. Also, the genome-wide evaluation of potential biomarkers for predicting treatment efficacy and toxicity becomes one of the significant approaches for the personalized medicine. Here, I will introduce the current status of genome-based drug development approaching personalized treatment in gastric cancer.
abstracts
After trastuzumab was introduced in treatment of Her-2 positive gastric cancer(GC), there are no specific and effective molecular targeted agents (MTA) in gastric cancer,
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v17/2240151 by guest on 14 March 2018